Perrigo launches generic version of Neptazane tablets
The product is a component of the contingent rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its
BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.
The company is exclusively manufacturing the approved hemophilia A therapy drug Kogenate FS/Kogenate Bayer at its Berkeley facility in California. According to Bayer, establishing an additional supply source
XARTEMIS XR’s release profile combines Mallinckrodt’s newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed’s advanced Acuform drug delivery technology. The drug is the first
With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs, and diagnostics, known as medical countermeasures,